Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- B-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Lymphoblastic Lymphoma
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateDrug: cytarabineDrug: prednisoneDrug: bortezomibDrug: pegaspargaseDrug: methotrexateDrug: etoposide phosphateDrug: cyclophosphamideBiological: filgrastimDrug: leucovorin calciumOther: laboratory biomarker analysisDrug: High Dose MTX
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00873093
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
- Conditions
- Myeloma
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 160
- Registration Number
- NCT00871013
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 12
- Registration Number
- NCT00869752
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 90
- Registration Number
- NCT00869232
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
- Conditions
- MedulloblastomaPineoblastomaSupratentorial Embryonal Tumor, Not Otherwise Specified
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: Etoposide PhosphateDrug: IsotretinoinOther: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationDrug: ThiotepaDrug: Vincristine SulfateDrug: Vorinostat
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00867178
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis
- Conditions
- Germ Cell Tumors
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 101
- Registration Number
- NCT00864318
- Locations
- 🇫🇷
Hopital St André, Bordeaux, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Claudius Regaud, Toulouse, France
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
- Conditions
- Lymphoma
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Registration Number
- NCT00829205
- Locations
- 🇬🇧
Derriford Hospital, Plymouth, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
🇬🇧Barts and the London NHS Trust, London, England, United Kingdom
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
- Conditions
- Carcinoma, Small Cell
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Chonnam National University Hospital
- Target Recruit Count
- 147
- Registration Number
- NCT00826644
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
- Conditions
- LymphomaNonneoplastic Condition
- Interventions
- Biological: bleomycin sulfateDrug: BEACOPP regimenBiological: filgrastimDrug: ABVD regimenDrug: cyclophosphamideDrug: dacarbazineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: vinblastine sulfateDrug: prednisoneDrug: procarbazine hydrochlorideDrug: vincristine sulfate
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 371
- Registration Number
- NCT00822120
- Locations
- 🇺🇸
Kaiser Foundation Hospital - San Rafael, San Rafael, California, United States
🇺🇸Illinois CancerCare - Macomb, Macomb, Illinois, United States
🇺🇸Saint Michael's Hospital Cancer Center, Stevens Point, Wisconsin, United States
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: RG1507Drug: RO1507Drug: erlotinib [Tarceva]Drug: bevacizumab [Avastin]Drug: pemetrexelDrug: carboplatinDrug: capecitabine [Xeloda]Drug: sorafenibDrug: temozolomideDrug: cetuximabDrug: paclitaxelDrug: etoposideDrug: mFOLFOX6Drug: trastuzumab [Herceptin]Drug: docetaxelDrug: gemcitabineDrug: irinotecan
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT00811993
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.